Inhibrx Biosciences, Inc. (INBX): R&D Expense
$113.03M
Year ended 2025-12-31
$103.00M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $113.03M | -44.5% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $203.74M | +6.3% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $191.64M | n/a | 2025-03-17, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $113.03M | -44.5% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $2.37M | -57.2% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $27.18M | -34.9% |
| Pluri Inc. (PLUR) | 2026-06-30 | $15.09M | +17.4% |
| Prokidney Corp. (PROK) | 2025-12-31 | $114.12M | -10.6% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $69.30M | -21.8% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $28.52M | -11.2% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $69.45M | -1.2% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $35.33M | -4.1% |
Compare INBX, SCNI, OTLK, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗